Paragon 28 (FNA): Utang-utang marang kapitalisasi buku

Logo korporat perusahaan Paragon 28 Inc. (FNA)

Paragon 28, Inc. (FNA) relies on a fabless model with shipment control managed through its own hub. The financial leverage trend on the balance sheet via GURU.Markets confirms stability, where 0.87 represents the latest metric reading. Revenues depend on insurance reimbursements and physician training, while outsourcing the production of titanium systems to external factories minimizes operational design risks.

Paragon 28 Inc. - Utang-utang marang kapitalisasi buku FNA (periode 04.07.2022 - 26.04.2025)
Produk merek Paragon 28 Inc.

Paragon 28, Inc. (FNA) dominates a niche segment of foot and ankle implants, ensuring high operational efficiency. This success is reflected in the metric structure by comparing all creditor obligations against the net asset value. The indicator measures the extent to which business development depends on borrowed funds relative to equity. High leverage can accelerate expansion but increases financial risks. The trend in the ratio of the company's financial debt to balance sheet capital allows for an assessment of this strategy's sustainability.

Pesaing Paragon 28, Inc.

Boston Scientific - Utang-utang marang kapitalisasi buku|Utang marang nilai buku edwards.com EW|Utang-utang marang kapitalisasi buku RMD (ResMed)|PODD - Utang-utang marang aset resik|ZBH: Utang-utang marang kapitalisasi buku|COO (CooperSurgical) - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Align Technology, Inc.|Rasio utang marang kapitalisasi buku globusmedical.com|TMDX (TransMedics Organ Care System) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik Alphatec Holdings ATEC|Artivion Inc (AORT) - Utang marang nilai buku|Rasio utang-utang marang kapitalisasi buku Enovis Inc. ENOV|IART (Integra LifeSciences) - Utang-utang marang kapitalisasi buku|ESTA - Utang-utang marang nilai buku|Utang-utang marang kapitalisasi buku Beta Bionics|Rasio utang marang nilai buku IRADIMED Corp|EMBC - Utang marang nilai buku|Rasio utang marang aset resik TNDM|Rasio utang marang kapitalisasi buku AXGN (AxoGen, Inc.)|Utang marang nilai buku si-bone.com (SIBN)|OFIX: Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku Bioventus Inc BVS|OrthoPediatrics Inc. (KIDS) - Utang-utang marang kapitalisasi buku|TMCI - Rasio utang marang nilai buku|Strata Critical Medical Inc - Utang-utang marang kapitalisasi buku|carlsmed.com (CARL) - Utang-utang marang aset resik|Utang-utang marang kapitalisasi buku RXST|Utang marang nilai buku ClearPoint|Utang-utang marang kapitalisasi buku STXS|Utang-utang marang kapitalisasi buku STIM (Neuronetics, Inc)|Rasio utang marang kapitalisasi buku Sight Sciences, Inc. SGHT|OBIO - Rasio utang marang kapitalisasi buku|Utang marang nilai buku Anika (ANIK)|NSPR - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku ZJYL|VANI (Vivani Medical) - Utang-utang marang nilai buku|Xtant Medical Holdings, Inc. - Rasio utang marang kapitalisasi buku|Utang marang aset resik n1mtc.com (NMTC)|Utang marang nilai buku MODD|Utang-utang marang kapitalisasi buku Myomo Inc. (MYO)|Utang-utang marang kapitalisasi buku COCH|Vivos Therapeutics Inc - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku enVVeno Medical|SINT: Rasio utang-utang marang kapitalisasi buku|TNON (Tenon Medical) - Rasio utang marang kapitalisasi buku|ReWalk Robotics (LFWD) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku AMIX (Autonomix Medical Inc.)|Utang-utang marang nilai buku IVF|Rasio utang marang kapitalisasi buku Bone Biologics BBLG|Rasio utang marang nilai buku axonics.com AXNX|Utang marang nilai buku BIOLASE (BIOL)|Dynatronics Corp - Utang marang modal buku|Rasio utang marang kapitalisasi buku INVO Bio